Evidence map›Paper›PMID 42747616›Full record

Trial reportBreast cancer research and treatment2026

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial.

F Schochter, T W P Friedl, H Schäffler, F Meier-Stiegen, K N Pfister, S Riethdorf, L Wiesmüller, H Neubauer, L Müller, P Wimberger and 11 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02035813 (DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02035813 phase2completednot on this map

DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

TypeinterventionalSponsorProf. Wolfgang JanniRan2014 to 2024Enrolled116ConditionsHER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female PatientsArmsRibociclib, Eribulin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

F SchochterDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany. fabienne.schochter@uni-ulm.de.ORCID http://orcid.org/0000-0003-3675-6494
T W P FriedlDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
H SchäfflerDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
F Meier-StiegenDepartment of Obstetrics and Gynecology, University Hospital Düsseldorf, Düsseldorf, Germany.
K N PfisterDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
S RiethdorfInstitute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
L WiesmüllerDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
H NeubauerDepartment of Obstetrics and Gynecology, University Hospital Düsseldorf, Düsseldorf, Germany.
L MüllerStudienzentrum UnterEms, Leer, Germany.
P WimbergerDepartment of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany.
P A FaschingDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
R LorenzStudien GbR Braunschweig, Braunschweig, Germany.
T HempelGesundheit Nord, Klinikumverbund Bremen, Bremen, Germany.
S HeubleinDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
A HartkopfDepartment of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
K PantelInstitute of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
B RackDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
V MüllerDepartment of Gynecology and Obstetrics, University Hospital Hamburg- Eppendorf, Hamburg, Germany.
T FehmDepartment of Obstetrics and Gynecology, University Hospital Düsseldorf, Düsseldorf, Germany.
W JanniDepartment of Obstetrics and Gynecology, Ulm University, 89075, Ulm, Germany.
J P CieslikDepartment of Obstetrics and Gynecology, University Hospital Düsseldorf, Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEribulin is a non-taxane microtubule inhibitor that showed survival benefits for pretreated metastatic breast cancer (MBC) patients. Circulating tumor cells (CTCs) are a prognostic marker, but their role in predicting response to specific MBC treatments is less clear. In this trial, we assessed the clinical outcome and its association with CTC-dynamics in HER2-negative MBC treated with eribulin. PATIENTS AND

methodsHER2-negative MBC-patients were screened for CTCs within the DETECT study program using the CellSearch® technology (Menarini Silicon Biosystems; Bologna, Italy). Patients with HER2-negative CTCs were eligible for the single-arm DETECT-IVb study treatment with eribulin. Primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), CTC-clearance rate and safety.

resultsMedian PFS and OS were 4.6 months and 13.4 months, respectively. Multivariable adjusted analyses showed that patients with CTC-clearance at first follow-up (34.7%) had significantly improved PFS (p = 0.043) but not OS (p = 0.192) compared to patients with at least 1 CTC. Likewise, patients with CTC-clearance at the end of the treatment (23.1%) achieved a significantly better PFS (p = 0.015) but not OS (p = 0.218). Neutropenia, leukopenia, anemia and fatigue were the most common adverse events and no new or unexpected safety signals were obtained.

conclusionIn this trial, we could confirm eribulin as an effective treatment option in high-risk HER2-negative MBC. CTCs proved their role as a prognostic marker and our results support the potential role of CTC dynamics as an early biomarker of treatment response to eribulin.

trial registrationEudraCTNo2013-001269-18 http://ClinicalTrials.gov , TRN NCT02035813, Registration date 2014-01-12.

Indexed as

Antineoplastic AgentsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFuransKetonesNeoplastic Cells, CirculatingAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedNeoplasm StagingPolyether PolyketidesPrognosisTreatment OutcomeAntineoplastic AgentsBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonesPolyether PolyketidesCirculating tumor cellsCTC clearanceEfficacyEribulinMetastatic breast cancerSafety

Identifiers

PMID42747616
PMCPMC13582096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.